


Figure 1B




Figure 1A

Figure 1




Intradermal
Subcutaneous
Intramuscular
Human EPO Protein (pg/mL Serum)
2500
2000
1500
1000
500
0
1 ug
10 ug
50 ug
6 hr
1 ug
10 ug
50 ug
24 hr
Dose Administration

Figure 2

Figure 3


Untreated
Subcutaneous
Intradermal
Intramuscular
Liver
Lung
Heart
Spleen
Kidney
Inguinal Lymph Nodes
Injected Muscles
Axillary Lymph Nodes
Brachial Lymph Nodes




Untreated
ML-2
ICE
Target 23
Chol-SS-DMA
DLin-SS-DMA
CCBene
Liver
Heart
Kidney
Lung
Spleen
Inguinal Lymph Nodes
Axillary Lymph Nodes
Injected Muscles
Brachial Lymph Nodes

Figure 4

Figure 5


CCBene
ICE
ML-2
C12-200
DLin-SS-DMA
hEPO Protein (ng/mL Serum)
hEPO Protein (µg/mL Serum)
Traditional
ReMix



Average total flux
40,000,000
35,000,000
30,000,000
25,000,000
20,000,000
15,000,000
10,000,000
5,000,000
0
Liver
Heart
Kidneys
Muscles
Lungs
Spleen
Inguinal LN
Axillary LN
Brachial LN

Figure 6